HIF1A and Parkinson disease: First, in various cellular and animal models of PD (toxin and α-synuclein-overexpression models), pharmacological strategies that enhance HIF stability/activity (e.g., using HIF-inducing iron chelators like deferoxamine, the HIF-activator agmantin, prolyl hydroxylase inhibitors like FG-4592, or the HIF-1α-transcription-enhancing compound albendazole) have been shown to be beneficial [74,75,76,77,78,79,80].